Fang Cheng, Cao Yue, Liu Xiaoping, Zeng Xian-Tao, Li Yirong
Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Center for Evidence-Based and Translation Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Oncotarget. 2017 Jul 12;8(38):63963-63970. doi: 10.18632/oncotarget.19246. eCollection 2017 Sep 8.
Detection of serum tumor markers has been developed as a non-invasive tool to assess treatment efficiency in different types of cancer. This study aims to investigate the role of preoperative serum tumor markers (CEA, CA125 and CA15-3) in the management of breast cancer, and their relationships with patients' clinicopathological parameters as well as different molecular subtypes. Altogether, 151 patients with invasive breast cancer and 180 control subjects with benign breast diseases were enrolled in this study. In the present study, preoperative serum levels of CEA, CA125 and CA15-3 were significantly higher in patients with breast cancer than controls subjects. Moreover, late-stage cancer patients exhibited significantly higher levels of CEA, CA125 and CA15-3 compared with early-stage ones. Statistical analysis indicated that elevated CA125 and CA15-3 levels were obviously related to patients with larger tumor diameter (>5cm) and lymph node metastasis. Furthermore, our results showed that the preoperative serum levels of CA125 exhibited statistical differences among various molecular subtypes, with the most frequent elevations occurring in the triple-negative tumors. In summary, our study indicated that the preoperative serum levels of CEA, CA125 and CA15-3 might be more efficient for monitoring advanced tumors than early diagnosis. High preoperative CA125 levels may reflect tumor burden and are associated with aggressive molecular subtype, suggesting that it can be used to predict poor outcome and prognosis of breast cancer patients.
血清肿瘤标志物检测已发展成为一种用于评估不同类型癌症治疗效果的非侵入性工具。本研究旨在探讨术前血清肿瘤标志物（癌胚抗原、糖类抗原125和糖类抗原15-3）在乳腺癌管理中的作用，以及它们与患者临床病理参数和不同分子亚型的关系。本研究共纳入151例浸润性乳腺癌患者和180例乳腺良性疾病对照者。在本研究中，乳腺癌患者术前血清癌胚抗原、糖类抗原125和糖类抗原15-3水平显著高于对照者。此外，晚期癌症患者的癌胚抗原、糖类抗原125和糖类抗原15-3水平明显高于早期患者。统计分析表明，糖类抗原125和糖类抗原15-3水平升高与肿瘤直径较大（>5cm）和淋巴结转移患者明显相关。此外，我们的结果显示，术前血清糖类抗原125水平在各种分子亚型之间存在统计学差异，在三阴性肿瘤中升高最为常见。总之，我们的研究表明，术前血清癌胚抗原、糖类抗原125和糖类抗原15-3水平对晚期肿瘤的监测可能比早期诊断更有效。术前糖类抗原125水平高可能反映肿瘤负荷，并与侵袭性分子亚型相关，表明它可用于预测乳腺癌患者的不良结局和预后。
